IBB – iShares Biotechnology ETF
iShares Biotechnology ETF (IBB) is a Health ETF, issued by iShares, $10.7B in assets, 0.46% expense ratio.
Returns as of Oct 23, 2026: 1 week +2.8%, 1 year +34.0%.
Invests 80%+ in underlying index components. May use futures, options, and swaps for up to 20%. Non-diversified biotechnology sector focus.
Top holdings
- AMGN – Amgen Inc, 8.5%
- GILD – Gilead Sciences Inc, 8.3%
- VRTX – Vertex Pharmaceuticals Inc, 7.8%
- REGN – Regeneron Pharmaceuticals Inc, 6.0%
- MRNA – Moderna Inc, 5.1%
- NTRA – Natera Inc, 4.0%
- ARGX – argenx NV ADR, 3.3%
- ILMN – Illumina Inc, 3.0%
- BIIB – Biogen Inc, 2.5%
- RVMD – Revolution Medicines Inc, 2.5%
- ONC – BeiGene, Ltd., 2.4%
- ALNY – Alnylam Pharmaceuticals Inc, 2.0%
- UTHR – United Therapeutics Corporation, 1.8%
- INCY – Incyte Corporation, 1.7%
- GMAB – Genmab AS, 1.6%
- INSM – Insmed Inc, 1.5%
- ROIV – Roivant Sciences Ltd, 1.3%
- CRL – Charles River Laboratories, 1.1%
- EXEL – Exelixis Inc, 1.1%
- MEDP – Medpace Holdings Inc, 1.0%
- ASND – Ascendis Pharma AS, 1.0%
- NBIX – Neurocrine Biosciences Inc, 1.0%
- HALO – Halozyme Therapeutics Inc, 0.9%
- TECH – Bio-Techne Corp, 0.8%
- BBIO – BridgeBio Pharma Inc, 0.8%